Mumbai company aims for significant growth with improved profitability
Mumbai’s Supriya Lifescience Ltd is discussing with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products, says its managing director Dr Saloni Wagh.
She disclosed this in the latest financial report on 13 Aug, saying, “Moving forward, the company aims for significant growth with improved profitability bse .”
The company achieved a record capital expenditure of Rs.146 crore in the last financial year nse .
Dr Wagh also unveiled the company’s new R&D facility at Lote Parshuram and anticipated the completion of Ambernath lab by early Q2FY25 sbi .
“These state-of-the-art centres will drive our next phase of growth, focusing on advanced product development and expanding our portfolio to meet evolving market needs ils.res.in/ .”
In the first quarter of FY25, Supriya Lifescience witnessed remarkable growth in its revenue, reporting a 21.7 % year-over-year increase, reaching Rs.160.63 crore compared to Rs.132.02 crore in Q1 FY24 globalpharmaexpo.
Profit After Tax (PAT) for Q1 FY25 came at Rs.44.64 crore, compared to Rs.28.51 crore in Q1 FY24 pharmapackeurope .
Supriya Lifescience is a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic thepharmacyshow .
The company said its cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. It has facility in Khed, District Ratnagiri, and globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and 14 active USDMFs. EHS requirements and ethical principles guide our core business. Fiinews.com
